Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation

BCL-2 family proteins are frequently aberrantly expressed in mantle cell lymphoma (MCL). Recently, the BCL-2-specific inhibitor venetoclax has been approved by the US Food and Drug Administration for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). In MCL, venetoclax has shown pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Thus, Yvonne J., de Rooij, Martin F.M., Swier, Nathalie, Beijersbergen, Roderick L., Guikema, Jeroen E.J., Kersten, Marie-José, Eldering, Eric, Pals, Steven T., Kater, Arnon P., Spaargaren, Marcel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Non-Hodgkin Lymphoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973496/
https://www.ncbi.nlm.nih.gov/pubmed/36226498
http://dx.doi.org/10.3324/haematol.2022.281668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973496/
https://www.ncbi.nlm.nih.gov/pubmed/36226498
http://dx.doi.org/10.3324/haematol.2022.281668

Ejemplares similares